Abacus (ABX) Q2 2026 Earnings Call Transcript

Abacus Global Management reported Q2 2026 revenue of $73.0M (+30% YoY) and adjusted net income of $27.1M (+24% YoY, exceeding its $24M–$26M guidance range), with adjusted EPS of $0.28 (+22% YoY). Adjusted EBITDA rose 27% YoY to $39.9M and the adjusted EBITDA margin held at 54.7% (~flat vs 56.1% prior year), while Q2 guidance for Q3 was raised/maintained at $26M–$28M adjusted net income and $0.26–$0.28 adjusted EPS. The company also drove strong balance-sheet/origination metrics (capital deployed $197.9M in Q2, +62% YoY; average realized gain ~25% vs a 20%+ target) and announced the SEC-effective launch of its first registered interval fund (ABXGX), alongside LifeARC tokenization/infrastructure build-out.

Analysis

ABXL’s real story is not the beat; it is the migration from a capital-intensive originations model to a fee-and-distribution flywheel. In the next 1-3 months, the interval fund and Manning channel are the important catalysts because they can lower the effective cost of capital and raise deployment velocity, which should mechanically support realized gains and ROE if inflows hold. That said, the market should not extrapolate the current earnings cadence linearly; the upside is more about mix shift and multiple expansion than a step-change in current-quarter EPS.

The second-order winner is ABXL’s own platform economics, plus RIAs/custodians that want an uncorrelated yield product without daily-liquidity mismatch. The losers are smaller life-settlement intermediaries and any private-credit manager competing for the same “alternative income” dollars, because ABXL’s proposition is cash-validated rather than mark-dependent. Tokenization and LifeARC are strategically important, but near-term monetization is still more optionality than hard revenue; their main impact is improving transparency and widening distribution, which could compress spreads in the secondary policy market over 6-18 months.

The main risk is that the stock gets ahead of the fee-related earnings ramp. If fund inflows slow, securitization slips, or realized policy gains revert toward the low-20% range, the multiple can compress quickly because the current setup assumes smooth execution and rising recurring revenue. The contrarian read is that the market may be underestimating the durability of the origination moat but overestimating how quickly LifeARC becomes material to P&L.

Key Decisions for Investors

• Long ABXL on a 1-2 week post-print pullback; target 10-15% upside over 3 months if Q3 inflows and deployment stay on track, with a thesis break if longevity inflows drop below ~$200M/quarter or realized gains fall under 20%.
• Pair trade: long ABXL / short BIZD over the next 1-3 months to express the shift from mark-sensitive private credit into cash-validated alternative yield; this is highest-conviction if private credit redemption headlines persist.
• If options are liquid, buy 3-6 month ABXL call spreads into the next securitization/inflow catalyst; use spreads rather than outright calls because the upside is execution-dependent and downside can be sharp if the monetization timeline slips.
• Add only on confirmation that fee-paying AUM trends toward the high end of management’s path into year-end; if the interval fund launch underwhelms or AUM growth stalls, fade rallies rather than average down.